Narjust Florez, Co Director of the Young Lung Cancer Program at Dana-Farber Cancer Institute, shared on LinkedIn:
“The future of early-stage lung cancer is being written in real time.
Today at Bridging the Gaps Lung ILCC 2026, we tackled one of the biggest questions in thoracic oncology:
What comes after neoadjuvant therapy?
From pathologic response and ctDNA to surveillance strategies.”
Other articles about lung cancer on OncoDaily.